A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast Cancer

K
Kathy Miller, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body.

Description

The purpose of this study is to evaluate whether the addition of entinostat to endocrine therapy (exemestane) improves progression-free survival (PFS) and/or overall survival (OS) in postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have previously progressed on a non-steroidal aromatase inhibitor (Al).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Breast Cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1403644196

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center